World's Best Scientists 2026 revealed!
Remo Panaccione

Remo Panaccione

D-Index & Metrics

Medicine

D-Index
104
Citations
59535
World Ranking
6908
National Ranking
263

Overview

Remo Panaccione is affiliated with the University of Calgary in Canada. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions to subfields such as Genetics, Epidemiology, Surgery, Immunology, and Oncology.

Their main research topics focus on several gastrointestinal and immunological conditions including:

  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Eosinophilic Esophagitis
  • Immunodeficiency and Autoimmune Disorders
  • Autoimmune and Inflammatory Disorders
  • Colorectal Cancer Treatments and Studies
  • Celiac Disease Research and Management

Remo Panaccione has contributed to several influential papers in high-impact journals, including:

  • "Crohn's disease," 2020, Nature Reviews Disease Primers
  • "Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials," 2022, The Lancet
  • "Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials," 2022, The Lancet
  • "Upadacitinib Induction and Maintenance Therapy for Crohn's Disease," 2023, New England Journal of Medicine
  • "Increased Intestinal Permeability Is Associated With Later Development of Crohn's Disease," 2020, Gastroenterology

The frequent publication venues where Panaccione's work appears include:

  • Gastroenterology
  • Journal of Crohn s and Colitis
  • The American Journal of Gastroenterology
  • Journal of the Canadian Association of Gastroenterology
  • Inflammatory Bowel Diseases

The scientist often collaborates with several researchers in their field, notably:

  • Silvio Danese
  • Gilaad G. Kaplan
  • Geert D'Haens
  • Laurent Peyrin-Biroulet
  • Christopher Ma

Best Publications

  • Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

    Natalie A. Molodecky;Ing Shian Soon;Doreen M. Rabi;William A. Ghali

  • Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

    Siew C Ng;Hai Yun Shi;Hai Yun Shi;Nima Hamidi;Fox E Underwood

  • Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

    Jean–Frédéric Colombel;William J. Sandborn;Paul Rutgeerts;Robert Enns

  • Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

    Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak

  • Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

    L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch

  • Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

    William J. Sandborn;Christopher Gasink;Long Long Gao;Marion A. Blank

  • Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial

    William J Sandborn;Stephen B Hanauer;Paul J Rutgeerts;Richard N Fedorak

  • Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

    William J. Sandborn;Paul Rutgeerts;Robert Enns;Stephen B. Hanauer

  • The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.

    David A. Schwartz;Edward V. Loftus;William J. Tremaine;Remo Panaccione

  • Natalizumab induction and maintenance therapy for Crohn's disease.

    William J. Sandborn;Jean Frédéric Colombel;Roberts Enns;Brian G. Feagan

  • Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

    Remo Panaccione;Subrata Ghosh;Stephen Middleton;Juan R. Márquez

  • Crohn's disease

    Giulia Roda;Siew Chien Ng;Paulo Gustavo Kotze;Marjorie Argollo

  • Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies

    Alexandra D. Frolkis;Jonathan Dykeman;María E. Negrón;Jennifer deBruyn

  • The safety of vedolizumab for ulcerative colitis and Crohn's disease

    Jean Frédéric Colombel;Bruce E. Sands;Paul Rutgeerts;William Sandborn

  • Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

    Jean Frederic Colombel;Remo Panaccione;Peter Bossuyt;Milan Lukas

  • Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

    Walter Reinisch;William J Sandborn;Daniel W Hommes;Geert D'Haens

  • Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

    Gerd R Burmester;Remo Panaccione;Kenneth B Gordon;Melissa J McIlraith

  • Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

    Stephan R. Targan;Brian G. Feagan;Richard N. Fedorak;Bret A. Lashner

  • Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host.

    Jaclyn Strauss;Gilaad G. Kaplan;Paul L. Beck;Kevin Rioux

  • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response

    Geert R. D'Haens;Remo Panaccione;Peter D.R. Higgins;Severine Vermeire

Frequent Co-Authors

Gilaad G. Kaplan
Gilaad G. Kaplan University of Calgary
Subrata Ghosh
Subrata Ghosh University College Cork
William J. Sandborn
William J. Sandborn University of California, San Diego
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai
Brian G. Feagan
Brian G. Feagan University of Western Ontario
Edward V. Loftus
Edward V. Loftus Mayo Clinic
Walter Reinisch
Walter Reinisch Medical University of Vienna
Geert R. D'Haens
Geert R. D'Haens University of Amsterdam
Silvio Danese
Silvio Danese Vita-Salute San Raffaele University
Laurent Peyrin-Biroulet
Laurent Peyrin-Biroulet University of Lorraine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine or nursing in the USA? There are now more flexible and affordable options available through online degree programs. Many students start with rn to bsn online programs to advance their qualifications while balancing work and family. Those seeking to become nurse practitioners or leaders can explore direct entry msn programs online, even if their undergraduate degree is in another field.

Cost is often a major concern. Fortunately, there are numerous affordable options, such as the cheapest dnp online program, allowing nurses to further their education without the burden of heavy debt. Admissions competitiveness can also be a hurdle. If you are searching for easier access points into the field, you might be interested in learning what is the easiest nursing program to get into for your qualifications.

With these pathways, you can tailor your medical or nursing career to suit your goals, timeline, and budget, all from the comfort of your home.

Best Scientists Citing Remo Panaccione

Trending Scientists